PDE9 inhibitors for treating sickle cell disease
US12213975B2 · kind B2 · utility
0Cited by
54References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 26, 2021 |
| Grant date | Feb 4, 2025 |
| Priority date | — |
| Expiry date | Dec 20, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to PDE9 inhibitors, pharmaceutical compositions comprising the PDE9 inhibitors, and methods of using the PDE9 pharmaceutical compositions for the treatment of sickle cell disease (SCD).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.